Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte

ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.

Finance Watch Image
• Source: Shutterstock

Summer may be over, but the heat is rising in the world of biopharmaceutical financings with some big private and public company financings announced just after the 2 September Labor Day holiday, the de facto end of summer in the US. Arsenal Biosciences, Inc. (ArsenalBio) unveiled one of the largest venture capital financings so far this year, to fund clinical development of its autologous programmable chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors.

More from Finance Watch

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By 

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.

Finance Watch: Cargo Restructuring Not The News The IPO Market Needs

 
• By 

Public Company Edition: Cargo suspended development and cut 90% of its workforce to focus on strategic alternatives, while Pyxis and Kiromic laid off or furloughed employees. Also, Pfizer sold its remaining Haleon shares for $3.3bn, Galderma sold $1bn in bonds and other financings.

Finance Watch: Venture Capital Mega-Rounds Attempt A Rebound In March

 
• By 

Private Company Edition: There have been five $100m-plus VC rounds so far this month, up from three in all of February. Flagship unveiled Lila Sciences with $200m, while Curevo and Insilico raised $110m in series B and E rounds, respectively. Also, Arbor Biotech garnered $73.9m.

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On

 
• By 

Restructuring Edition: Biopharma companies used fourth-quarter updates to reveal job and program cuts to conserve cash, including Sutro, Agenus, Coherus, Inozyme and Atea. Also, Vincerx’s reverse merger was terminated and Vaccinex, Oncternal, Syros plan to voluntarily delist.

More from Financing

Major Cash Injection Advances Augustine’s HDAC6 Hopes

 
• By 

The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.

Korea Needs To Think Bigger On M&As: KHIDI

 

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.

Finance Watch: Cargo Restructuring Not The News The IPO Market Needs

 
• By 

Public Company Edition: Cargo suspended development and cut 90% of its workforce to focus on strategic alternatives, while Pyxis and Kiromic laid off or furloughed employees. Also, Pfizer sold its remaining Haleon shares for $3.3bn, Galderma sold $1bn in bonds and other financings.